Last reviewed · How we verify
Whole blood donation
At a glance
| Generic name | Whole blood donation |
|---|---|
| Sponsor | Etablissement Français du Sang |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Treatment of Hemochromatosis (PHASE2)
- Improving White Blood Cell Collection From Healthy Donors (PHASE4)
- Transcriptional Responses as an Indicator of Individualised Responses to Radiation Effects (RTGene 2)
- Association of TNFAIP3 With Immune-mediated TTP (NA)
- Autologous Whole Blood Management for Transfusion Reduction in Adult Cardiac Surgery Patients (NA)
- Pesticides and Infertility: Oxidative Stress Via Circulating Cell-free DNA and Gut/Genital Microbiome Signatures in Women With Endometriosis (NA)
- Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection (PHASE1)
- Restrictive Fluid Management In Liver Transplantation (REFIL) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Whole blood donation CI brief — competitive landscape report
- Whole blood donation updates RSS · CI watch RSS
- Etablissement Français du Sang portfolio CI